Skip to main content
Article thumbnail
Location of Repository

A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK

By Lee Moore, Vanessa Remy, Monique Martin, Maud Beillat and Alistair McGuire
Topics: HB Economic Theory, RA Public aspects of medicine
Publisher: Resource Allocation
Year: 2010
DOI identifier: 10.1186/1478-7547-8-7
OAI identifier: oai:eprints.lse.ac.uk:35383
Provided by: LSE Research Online

Suggested articles

Citations

  1. (2005). Annemans L: Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics doi
  2. (2001). Birnie E: The discount rate in the economic evaluation of prevention: a thought experiment. doi
  3. (2007). Cost-Effectiveness of Herpes Zoster Vaccine: Flawed Assumptions Regarding Efficacy against Postherpetic Neuralgia. Clinical Infectious Diseases doi
  4. (2000). Dworkin RH: The management of post-herpetic neuralgia. doi
  5. (2003). Dworkin RH: Treatment of herpes zoster and postherpetic neuralgia. BMJ doi
  6. (2009). Edmunds WJ: Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine doi
  7. (2006). EM: The burden of neuropathic pain: results from a cross-sectional survey. doi
  8. (2009). Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect doi
  9. (2002). Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. doi
  10. (1993). Epidemiology, outcome and control of varicella-zoster infection. Rev Med Micro doi
  11. (2007). Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine doi
  12. (2005). FF: Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ doi
  13. (2004). for Clinical Excellence: Guide to the methods of technology appraisal.
  14. (2002). GA: Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract
  15. (2004). Hospital Episodes Statistics Data
  16. (2001). JD: The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine doi
  17. (2000). Management of Herpes Zoster (Shingles) and Postherpetic Neuralgia. American Family Physician
  18. (2005). medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. doi
  19. (1996). National Population Health Survey (NPHS) doi
  20. (2005). Netten A: Unit Costs of Health and Social Care
  21. (1998). O'Brien B: Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years.
  22. (2004). Oxman MN: Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. doi
  23. (1988). Prevention and Economics.
  24. (2002). RH: Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. doi
  25. (2000). RJ: Neurologic complications of the reactivation of varicellazoster virus. doi
  26. (2005). RP: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. doi
  27. (2007). Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. doi
  28. (2008). Silber JL: Zostavax Protocol 010 Study Group: A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol doi
  29. (2006). The burden of Herpes Zoster: a prospective population based study. Vaccine doi
  30. (2002). Whitley RJ: Clinical practice. Herpes zoster.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.